NPM1 and acute myeloid leukemia: ASXL1 prognosis in intermediate-risk cytogenetic AML and NPM1 mutations: For assessing the impacts of intermediate-risk cytogenetics and NPM1 mutations on the prognosis of ASXL1 mutations, we initially selected studies evaluating OS in AML patients with an intermediate-risk cytogenetic profile.